Medco Health Solutions, Inc., announced this week that it will conduct a clinical trial to assess whether clopidogrel bisulfate (Plavix®, Bristol-Myers Squibb and Sanofi-aventis) is just as effective as the newer drug prasugrel (Effient™, Eli Lilly and Company) in people who lack a genetic variation that inhibits their metabolism of clopidogrel. This new research has [...]

Tags: clopidogrel, clotting, comparative effectiveness research, CYP2C19, Effient, Francis Collins, heart, Medco, pharmacogenomics, Plavix, prasugrel

A new report in the Journal of the American Medical Association adds to the mounting evidence that genetic variations impact the efficacy of clopidogrel (Plavix®), a drug used to prevent blood clots in people who have had a heart attack or stroke and also those with peripheral artery disease and unstable angina.
Previous research has shown [...]

Tags: angina, clopidogrel, clotting, heart attack, JAMA, peripheral artery disease, Plavix, stroke

This Monday acting Surgeon General Steven K. Galson issued a Call to Action to reduce the number of people in the United States affected by two serious blood clotting conditions: deep vein thrombosis and pulmonary embolism.
Deep vein thrombosis (DVT), sometimes called “economy class syndrome” is the formation of a blood clot in a vein deep [...]

Tags: clotting, deep vein thrombosis, dvt, Factor V Leiden, pe, Prothrombin, pulmonary embolism, Surgeon General, venous thromboembolism, vte